Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Ariana Resources, Michelmersh, ReNeuron...

Mon, 12th Jul 2010 08:31

Shares in Ariana Resources rallied after the Turkey-focused gold miner announces the completion of its joint venture agreement with Proccea to develop the Red Rabbit Project in western Turkey.The group said results from the recent resource drilling programme are expected shortly. Managing director Kerim Sener said: "This JV has now put us firmly on the path towards becoming the next gold producer in Turkey, and has created a solid set of foundations to spur the growth of your company.""We are delighted to be in partnership with a strong and competent JV partner and we look forward to adding further value to our assets via this JV."Brickmaker Michelmersh's terracotta and faience production business has won six supply contracts for high profile projects in London. Products made by Hathern Terracotta, launched in August last year, will be used in the Savoy in the Strand, "a world renowned department store in Knightsbridge", the V&A in South Kensington, new Apple Store in Covent Garden, homes in St John's Wood and Barons Court Underground Station. New tests carried out by stem cell therapy group ReNeuron suggest CTX stem cells may play a role in promoting the functional recovery of stroke patients and suppress the inflammatory response associated with brain damage, aiding the natural healing processes in the brain."These latest findings further illustrate and potentially explain the potency of the CTX cells in assisting the body's own repair mechanisms in vascular conditions such as stroke and peripheral arterial disease, and suggest the potential utility of the cells to treat a much wider range of inflammatory diseases," said chief scientific officer John Sinden.TanzaniteOne has sold 191,673 carats of rough tanzanite at $13.4/carat during its third official sale of 2010 in Dubai, bringing in revenue of $2.57m.Sales in May and June have lifted second quarter revenue to $5.4m, up 80% on the first three months of the year and the best quarterly performance in two years. First half revenue rose to $8.4m."This extremely encouraging quarterly revenue has surpassed both our internal recovery projections as well as market expectations," said boss Bernard Olivier.Shares in Sweden-focused miner Beowulf Mining moved ahead after it revealed that initial results from its drilling programme at its wholly-owned Kallak iron ore deposit have shown commercial grades across the deposit.Shares in Best of the Best, which displays luxury cars as competition prizes in airports, climbed after results that suggest it is weathering economic difficulties. In the year to April 30, pre-tax profits slipped to £0.48m from £0.52m as revenues eased to £7.3m from £7.46m.Henderson Morley is still waiting for KMS to come up with the cash to complete the purchase of the rights to its ionic contra-viral therapy human portfolio and has granted a further extension until 14 July (Wednesday).Indian power supplier KSK Power's profits surged last year $76.9m from $8.6m, which included $31.8m (2009: $1.0m) from currency gains. Operating profit rose 118% to $26.3m. "With the commencement of power generation from VS Lignite Power and the first unit at Wardha Warora project, the anticipated new cash flow cycle has now begun," said KSK. "We remain on course to meet market expectations in 2011 and are confident in our ability to meet our longer term goals," it added.Kazakhstan focused Max Petroleum reports a recent study by Ryder Scott on the company's Blocks A&E licence ares showed total risked mean recoverable resources estimated at 1,100 million barrels of oil equivalent. Total unrisked mean recoverable resources estimated at 5,358 million barrels, distributed within a probable range (P90 to P10) of 2,004 million barrels to 8,847 million barrels."We are pleased that Ryder Scott's assessment of our portfolio, like our own, recognizes the significant potential of both the pre and post-salt prospects and leads we have identified on Blocks A & E," Jim Jeffs, executive co-chairman said.Canadian independent oil and gas company Ithaca Energy said it has signed and completed the senior secured borrowing base facility agreement for up to $140m announced on 22 April.Perpetual Income & Growth Investment Trust saw its net asset value per share total return slide 5.4% in the second quarter, a performance which still outshone that of the FTSE All-Share index, which fell 11.8% over the same period. Total gross assets at the end of June stood at £550.6m, down from £587.4m.Value & Income Trust, which invests in higher yielding, less fashionable areas of the UK commercial property and quoted equity markets, saw its net asset value (NAV) per share slide to 212.5p with debt at par value in the second quarter from 231.8p at the end of the first quarter.
More News
23 Nov 2021 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Nov 2021 12:20

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

Read more
26 Oct 2021 19:06

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Read more
26 Oct 2021 14:02

ReNeuron enters cancer therapy collaboration with UCL

(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of immune cells from induced pluripotent stem cells (iPSCs), for anti-cancer cell therapies.

Read more
21 Oct 2021 16:40

Director dealings: Reneuron Group non-executive makes share purchase

(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.

Read more
21 Oct 2021 14:07

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:14

ReNeuron treats first Oxford patient as part of expanded study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.

Read more
11 Oct 2021 11:51

ReNeuron upbeat on positive data from Spain collaboration

(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery technology could effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

Read more
11 Oct 2021 11:05

IN BRIEF: ReNeuron gets positive results from exosome drug data

IN BRIEF: ReNeuron gets positive results from exosome drug data

Read more
11 Oct 2021 10:59

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Read more
1 Oct 2021 11:15

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

Read more
1 Oct 2021 10:33

ReNeuron gets approval to restart RP clinical study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.

Read more
9 Sep 2021 16:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
6 Aug 2021 10:55

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.